Limited Offer
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Immunotherapy
- 1st Edition, Volume 5 - December 1, 2029
- Editors: Kasuya Hideki, Itzel Bustos Villalobos
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 2 2 9 1 4 - 9
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 2 9 1 5 - 6
Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Immunotherapy discusses current and under investigation treatments in pancreatic cancer. The book presents inform… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteBreaking Tolerance to Pancreatic Cancer Unresponsiveness to Immunotherapy discusses current and under investigation treatments in pancreatic cancer. The book presents information on how to combine current therapy with treatment under development and/or in clinical trials in order to improve survival. Chapters review new modalities to cure oncolytic viruses and Bi-specific T cell engager (BiTEs) as future clinical treatments, along with discussions on recent research using those modalities in combination therapy. The book is a valuable source for cancer researchers, oncologists and other members of the medical and biomedical field who are interested in learning more about new therapies.
- Discusses oncolytic virus in pancreatic cancer use, mainly herpes and adenoviruses, the results obtained on basic research, and clinical trials
- Encompasses knowledge on Bi-specific T cell engager (BiTEs), focusing on its function, development and use on pancreatic cancer
- Brings information on recently developed combination therapies that allow for a lower dose of treatment and hence less side effects
Cancer researchers, medical scientists, clinicians, graduate students
1. Pancreatic cancer generalities, current surgical treatment, updates
Dr. Norberto Sanchez
2. Current chemotherapy and immunotherapy in pancreatic cancer
Dr. Ivan Gonzales Espinoza
3. Generalities of Oncolytic virus and HF10 in pancreatic cancer
Dr Ichinose Toru, Dr. Yoshiki Hirooka4. Oncolytic Adenovirus use in pancreatic cancer
Dr. Masato Yamamoto, Dr. Mizuho Sato-Dahlman
5. BiTE cell generalities and its potential use for pancreatic cancer
Dr. Solange Paredes Moscosso
6. Precision oncology for pancreatic cancer
Dr. Juan W Valle
7. Strategies with immune therapy
Dr. Yoshiki Hirooka
8. Combination therapies of current/ new options to treat pancreatic cancer in future
Dr Itzel Bustos Villalobos, Dr. Kasuya Hideki
Dr. Norberto Sanchez
2. Current chemotherapy and immunotherapy in pancreatic cancer
Dr. Ivan Gonzales Espinoza
3. Generalities of Oncolytic virus and HF10 in pancreatic cancer
Dr Ichinose Toru, Dr. Yoshiki Hirooka4. Oncolytic Adenovirus use in pancreatic cancer
Dr. Masato Yamamoto, Dr. Mizuho Sato-Dahlman
5. BiTE cell generalities and its potential use for pancreatic cancer
Dr. Solange Paredes Moscosso
6. Precision oncology for pancreatic cancer
Dr. Juan W Valle
7. Strategies with immune therapy
Dr. Yoshiki Hirooka
8. Combination therapies of current/ new options to treat pancreatic cancer in future
Dr Itzel Bustos Villalobos, Dr. Kasuya Hideki
- No. of pages: 250
- Language: English
- Edition: 1
- Volume: 5
- Published: December 1, 2029
- Imprint: Academic Press
- Hardback ISBN: 9780128229149
- eBook ISBN: 9780128229156
KH
Kasuya Hideki
Dr Kasuya Hideki has graduated from medical career on 1990 at Aichi Medical University, Japan. He did his residency in general surgery, transplantation surgery and liver-pancreas surgery in Nagoya University, Japan. He also has experience in research including research fellowship at the division of surgical oncology at Massachusetts General Hospital, Harvard Medical School. Since then he is being involved in clinical as well as research work with focus on oncolytic virus, including its use, its generation and combination therapies with current approved therapies. In 2015, he started the laboratory of cancer immune therapy research center at Nagoya University as Chairman where he continues to do research on oncolytic virus and its use on pancreatic cancer.
Affiliations and expertise
Nagoya University, JapanIB
Itzel Bustos Villalobos
Dr Itzel Bustos Villalobos has graduated from medical career on 2002 from La Salle University, Mexico. She did internship in pediatrics and completed her PhD in pediatric oncology at the University of Nagoya, Japan. Posteriorly she did research in melanoma at the University of California, Davis with a broad experience in cancer immunology. Currently she works for the University of Nagoya at the Cancer Immune Therapy Research Center where she continues doing research on oncolytic virus in diverse types of cancer.
Affiliations and expertise
Cancer Immune Therapy Research Center, University of Nagoya